Assessment and treatment of irruptive cancer pain

Detalhes bibliográficos
Autor(a) principal: Santos, Juliana
Data de Publicação: 2015
Outros Autores: Raposo, Carina, Oliveira, António, Leonor Ribeiro, Ana
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://onco.news/index.php/journal/article/view/127
Resumo: The breakthrough cancer pain (BTCP) consists of a transitory exacerbation of pain that occurs either spontaneously or triggered by a specific factor (predictable or unpredictable), despite the relatively stable and adequate control of the background pain. It is essential to clearly identify that it is an episode of BTP and not a poorly controlled chronic pain.Pharmacological treatment can consist of rescue medication - Short Acting Opioid - SAO (eg. Sevredol®, Oramorph®) and Rapid Opioid Onset - ROO such as sublingual fentanyl sublingual, buccal film and transmucosal (eg. Abstral®, Breakyl® and Actiq®).It is essential nurses know how to make a proper assessment of BTP, how to teach the patient to manage the therapeutic regimen and how to reassess. The objectives of the reassessment determine the efficacy and tolerability of treatment of BTP and any change in its nature. Improper reassessment could lead to the continuation of an ineffective and/or inappropriate treatment.
id RCAP_065b2963873fbbf7bc1e67270fbe542c
oai_identifier_str oai:oai.onco.news:article/127
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Assessment and treatment of irruptive cancer painAvaliação e tratamento da dor irruptiva oncológicaDor irruptiva oncológicaDIOdor oncológicatratamento da dormorfinafentaniloBreakthrough Cancer PainBTCPoncologic painpain treatmentmorphinefentanylThe breakthrough cancer pain (BTCP) consists of a transitory exacerbation of pain that occurs either spontaneously or triggered by a specific factor (predictable or unpredictable), despite the relatively stable and adequate control of the background pain. It is essential to clearly identify that it is an episode of BTP and not a poorly controlled chronic pain.Pharmacological treatment can consist of rescue medication - Short Acting Opioid - SAO (eg. Sevredol®, Oramorph®) and Rapid Opioid Onset - ROO such as sublingual fentanyl sublingual, buccal film and transmucosal (eg. Abstral®, Breakyl® and Actiq®).It is essential nurses know how to make a proper assessment of BTP, how to teach the patient to manage the therapeutic regimen and how to reassess. The objectives of the reassessment determine the efficacy and tolerability of treatment of BTP and any change in its nature. Improper reassessment could lead to the continuation of an ineffective and/or inappropriate treatment.A dor irruptiva oncológica (DIO) é definida como uma exacerbação transitória da dor que ocorre quer espontaneamente quer desencadeada por um fator específico (previsível ou imprevisível), apesar do relativamente estável e adequado controlo da dor basal. É fundamental identificar claramente que se trata de um episódio de DIO e não de dor crónica basal mal controlada.O tratamento farmacológico consiste em medicação de resgate – formulações orais de libertação normal de morfina (p.ex. Sevredol®, Oramorph® - Short Acting Opioid - SAO) e formulações de libertação rápida como o fentanilo sublingual, película bucal e transmucoso (p.ex. Abstral®, Breakyl® e Actiq® - Rapid Onset Opioid - ROO).É essencial que os enfermeiros saibam realizar uma avaliação adequada da DIO, saibam ensinar o doente a gerir o esquema terapêutico e saibam reavaliar. Os objetivos da reavaliação são determinar a eficácia e tolerabilidade do tratamento da DIO e se houve ou não alguma alteração da sua natureza. Uma reavaliação inadequada pode levar à continuação de um tratamento ineficaz e/ou inapropriado.AEOP – Associação de Enfermagem Oncológica Portuguesa2015-09-10info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://onco.news/index.php/journal/article/view/127Onco.news; No. 28 (2015): Onco.News Journal; 10-18Onco.News; N.º 28 (2015): Revista Onco.News; 10-182183-69141646-7868reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://onco.news/index.php/journal/article/view/127https://onco.news/index.php/journal/article/view/127/140Direitos de Autor (c) 2023 Juliana Santos, Carina Raposo, António Oliveira, Ana Leonor Ribeiroinfo:eu-repo/semantics/openAccessSantos, JulianaRaposo, CarinaOliveira, AntónioLeonor Ribeiro, Ana2024-03-16T07:55:21Zoai:oai.onco.news:article/127Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:01:22.981329Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Assessment and treatment of irruptive cancer pain
Avaliação e tratamento da dor irruptiva oncológica
title Assessment and treatment of irruptive cancer pain
spellingShingle Assessment and treatment of irruptive cancer pain
Santos, Juliana
Dor irruptiva oncológica
DIO
dor oncológica
tratamento da dor
morfina
fentanilo
Breakthrough Cancer Pain
BTCP
oncologic pain
pain treatment
morphine
fentanyl
title_short Assessment and treatment of irruptive cancer pain
title_full Assessment and treatment of irruptive cancer pain
title_fullStr Assessment and treatment of irruptive cancer pain
title_full_unstemmed Assessment and treatment of irruptive cancer pain
title_sort Assessment and treatment of irruptive cancer pain
author Santos, Juliana
author_facet Santos, Juliana
Raposo, Carina
Oliveira, António
Leonor Ribeiro, Ana
author_role author
author2 Raposo, Carina
Oliveira, António
Leonor Ribeiro, Ana
author2_role author
author
author
dc.contributor.author.fl_str_mv Santos, Juliana
Raposo, Carina
Oliveira, António
Leonor Ribeiro, Ana
dc.subject.por.fl_str_mv Dor irruptiva oncológica
DIO
dor oncológica
tratamento da dor
morfina
fentanilo
Breakthrough Cancer Pain
BTCP
oncologic pain
pain treatment
morphine
fentanyl
topic Dor irruptiva oncológica
DIO
dor oncológica
tratamento da dor
morfina
fentanilo
Breakthrough Cancer Pain
BTCP
oncologic pain
pain treatment
morphine
fentanyl
description The breakthrough cancer pain (BTCP) consists of a transitory exacerbation of pain that occurs either spontaneously or triggered by a specific factor (predictable or unpredictable), despite the relatively stable and adequate control of the background pain. It is essential to clearly identify that it is an episode of BTP and not a poorly controlled chronic pain.Pharmacological treatment can consist of rescue medication - Short Acting Opioid - SAO (eg. Sevredol®, Oramorph®) and Rapid Opioid Onset - ROO such as sublingual fentanyl sublingual, buccal film and transmucosal (eg. Abstral®, Breakyl® and Actiq®).It is essential nurses know how to make a proper assessment of BTP, how to teach the patient to manage the therapeutic regimen and how to reassess. The objectives of the reassessment determine the efficacy and tolerability of treatment of BTP and any change in its nature. Improper reassessment could lead to the continuation of an ineffective and/or inappropriate treatment.
publishDate 2015
dc.date.none.fl_str_mv 2015-09-10
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://onco.news/index.php/journal/article/view/127
url https://onco.news/index.php/journal/article/view/127
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://onco.news/index.php/journal/article/view/127
https://onco.news/index.php/journal/article/view/127/140
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2023 Juliana Santos, Carina Raposo, António Oliveira, Ana Leonor Ribeiro
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2023 Juliana Santos, Carina Raposo, António Oliveira, Ana Leonor Ribeiro
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv AEOP – Associação de Enfermagem Oncológica Portuguesa
publisher.none.fl_str_mv AEOP – Associação de Enfermagem Oncológica Portuguesa
dc.source.none.fl_str_mv Onco.news; No. 28 (2015): Onco.News Journal; 10-18
Onco.News; N.º 28 (2015): Revista Onco.News; 10-18
2183-6914
1646-7868
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138187621171200

Registros relacionados